

\$210M raised to-date. It started with the first patient dosed at START.

A first-in-human, Phase 1 study of a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors

START DELIVERED

- First patient dosed at START Midwest (~Oct 2024) — the foundation for everything that followed.
- START Mountain Region site selected (Oct 2024).
- 20 patients enrolled across 2 START sites.
- Study featured at ASCO 2025 “Trials in Progress” (Drs. Nehal Lakhani & William McKean).



INVESTMENTS
TO DATE

~\$210M

raised across the biotech company

ADVANCING THE MISSION

SEPT 2024

\$90M Series D closed - Capital raised to fund the solid tumor Ph1 clinical program.

OCT 2024

First patient dosed at START Midwest - First patient dosed by Dr. Nehal Lakhani

DEC 2025

2nd development candidate nominated - another drug candidate added to the pipeline, proving out the platform.

MAY 2025

Study featured at ASCO 2025 “Trials in Progress” - START PIs, Drs. Nehal Lakhani (presenting first author) & William McKean.

JUN 2025

FDA Orphan Drug Designation - for small cell lung cancer, a regulatory foothold.

START HELPS BIOTECH:

✓ Increase Asset Value

✓ Hit Milestones Ahead of Schedule

✓ Protect Investments

